AstraZeneca announced Thursday that a US district court granted its request for a temporary restraining order barring Apotex from marketing a generic version of Pulmicort Respules (budesonide). The order will remain in effect until at least April 27, when the presiding judge will begin a hearing into whether Apotex’s version of the asthma medication should stay off the market until a patent infringement lawsuit involving the drug is resolved.

[ad]

Earlier this month, AstraZeneca filed a motion with the US District Court for the District of New Jersey, seeking to block Apotex’s generic product. AstraZeneca stated that patents for Pulmicort Respules continue until 2018, with paediatric exclusivity until 2019.

Source: FirstWord

Popularity: 2% [?]